Lakefront Biotherapeutics | GLPG - Operating Expenses

Stock Price
23.40
Daily Change
-0.38 -1.60%
Monthly
-5.26%
Yearly
-5.11%
Q2 Forecast
22.89

Lakefront Biotherapeutics reported EUR70.18M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
argenx SE USD 904M 10.57M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Genmab DKK 798M 235M Dec/2025
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
GRIFOLS EUR 1.45B 255.28M Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
Merck EUR 4.78B 669M Dec/2025
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
UCB EUR 2.96B 196M Dec/2025
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026